Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

Please visit answersincme.com/860/99485655-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) use a case-based approach to explore evidence-based strategies to optimize early-stage, resectable NSCLC care with (neo)adjuvant/perioperative immunotherapy, highlighting the role of multidisciplinary teams. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the (neo)adjuvant/perioperative treatment of patients with early-stage, resectable NSCLC; Formulate strategies to appropriately integrate immunotherapy-based (neo)adjuvant/perioperative regimens into treatment plans for patients with early-stage, resectable NSCLC; Discuss multidisciplinary team approaches to enhance care for patients with early-stage, resectable NSCLC.

There are no comments yet.

Please log in to write the first comment.